Answers are grounded in this paper and cite their sources.
AIMS: To describe conditional prognosis after redirection from neoadjuvant immunochemotherapy to definitive radiotherapy in stage III non-small cell lung cancer. PATIENTS AND METHODS: This single-center retrospective study estimated noncausal prognosis in 116 selected patients alive and progression-free 42 days after local treatment: neoadjuvant immunochemotherapy followed by redirected definitive thoracic radiotherapy (NICT-dCRT; n = 36; concurrent chemotherapy in 35), definitive concurrent chemoradiotherapy with consolidation immunotherapy (CRT-CI; n = 43), or surgery after neoadjuvant immunochemotherapy (NICT-S; n = 37). Progression-free survival (PFS) was primary; overall survival (OS) was secondary. Kaplan-Meier and restricted mean survival time (RMST) summaries were emphasized; Firth Cox associations were secondary and exploratory. Overlap weighting failed to achieve adequate balance. RESULTS: In NICT-dCRT and CRT-CI, median OS was 36.5 and 34.0 months, and median PFS was 17.1 and 13.4 months. Corresponding 24-month OS RMST was 20.59 and 20.86 months; PFS RMST was 16.63 and 15.24 months. Between-pathway RMST differences were imprecise. NICT-S had five PFS events and two deaths. CONCLUSIONS: These estimates describe pathway-specific conditional prognosis in clinically distinct post-landmark populations. Clinical selection, sparse events, and residual confounding preclude treatment-superiority or equivalence claims.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: